498 related articles for article (PubMed ID: 27975250)
1. Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain.
Thomas SN; Yang AJ
Methods Mol Biol; 2017; 1523():161-177. PubMed ID: 27975250
[TBL] [Abstract][Full Text] [Related]
2. Identification, Quantification, and Site Localization of Protein Posttranslational Modifications via Mass Spectrometry-Based Proteomics.
Ke M; Shen H; Wang L; Luo S; Lin L; Yang J; Tian R
Adv Exp Med Biol; 2016; 919():345-382. PubMed ID: 27975226
[TBL] [Abstract][Full Text] [Related]
3. Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach.
Thomas SN; Funk KE; Wan Y; Liao Z; Davies P; Kuret J; Yang AJ
Acta Neuropathol; 2012 Jan; 123(1):105-17. PubMed ID: 22033876
[TBL] [Abstract][Full Text] [Related]
4. Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States.
Haj-Yahya M; Lashuel HA
J Am Chem Soc; 2018 May; 140(21):6611-6621. PubMed ID: 29684271
[TBL] [Abstract][Full Text] [Related]
5. A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.
Ercan-Herbst E; Ehrig J; Schöndorf DC; Behrendt A; Klaus B; Gomez Ramos B; Prat Oriol N; Weber C; Ehrnhoefer DE
Acta Neuropathol Commun; 2019 Dec; 7(1):192. PubMed ID: 31796124
[TBL] [Abstract][Full Text] [Related]
6. Quantification of Tau Protein Lysine Methylation in Aging and Alzheimer's Disease.
Huseby CJ; Hoffman CN; Cooper GL; Cocuron JC; Alonso AP; Thomas SN; Yang AJ; Kuret J
J Alzheimers Dis; 2019; 71(3):979-991. PubMed ID: 31450505
[TBL] [Abstract][Full Text] [Related]
7. A validated antibody panel for the characterization of tau post-translational modifications.
Ercan E; Eid S; Weber C; Kowalski A; Bichmann M; Behrendt A; Matthes F; Krauss S; Reinhardt P; Fulle S; Ehrnhoefer DE
Mol Neurodegener; 2017 Nov; 12(1):87. PubMed ID: 29157277
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Protocol to Simultaneously Study Protein Phosphorylation, Acetylation, and N-Linked Sialylated Glycosylation.
Melo-Braga MN; Ibáñez-Vea M; Kulej K; Larsen MR
Methods Mol Biol; 2021; 2261():55-72. PubMed ID: 33420984
[TBL] [Abstract][Full Text] [Related]
9. Methylation as a key regulator of Tau aggregation and neuronal health in Alzheimer's disease.
Balmik AA; Chinnathambi S
Cell Commun Signal; 2021 May; 19(1):51. PubMed ID: 33962636
[TBL] [Abstract][Full Text] [Related]
10. Degradation or aggregation: the ramifications of post-translational modifications on tau.
Park S; Lee JH; Jeon JH; Lee MJ
BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
[TBL] [Abstract][Full Text] [Related]
11. Analysis of post-translational modifications in Alzheimer's disease by mass spectrometry.
Kelley AR; Bach SBH; Perry G
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2040-2047. PubMed ID: 30481587
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease.
Abreha MH; Dammer EB; Ping L; Zhang T; Duong DM; Gearing M; Lah JJ; Levey AI; Seyfried NT
Proteomics; 2018 Oct; 18(20):e1800108. PubMed ID: 30230243
[TBL] [Abstract][Full Text] [Related]
13. SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer's disease.
Bichmann M; Prat Oriol N; Ercan-Herbst E; Schöndorf DC; Gomez Ramos B; Schwärzler V; Neu M; Schlüter A; Wang X; Jin L; Hu C; Tian Y; Ried JS; Haberkant P; Gasparini L; Ehrnhoefer DE
Mol Neurodegener; 2021 Jul; 16(1):46. PubMed ID: 34215303
[TBL] [Abstract][Full Text] [Related]
14. Post-translational modifications within tau paired helical filament nucleating motifs perturb microtubule interactions and oligomer formation.
Acosta DM; Mancinelli C; Bracken C; Eliezer D
J Biol Chem; 2022 Jan; 298(1):101442. PubMed ID: 34838590
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic Tau Acetylation Is Coupled to Auto-Proteolytic Tau Fragmentation.
Cohen TJ; Constance BH; Hwang AW; James M; Yuan CX
PLoS One; 2016; 11(7):e0158470. PubMed ID: 27383765
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis of protein phosphorylation and ubiquitination in Alzheimer's disease.
Thomas SN; Cripps D; Yang AJ
Methods Mol Biol; 2009; 566():109-21. PubMed ID: 20058168
[TBL] [Abstract][Full Text] [Related]
17. JUMPptm: Integrated software for sensitive identification of post-translational modifications and its application in Alzheimer's disease study.
Poudel S; Vanderwall D; Yuan ZF; Wu Z; Peng J; Li Y
Proteomics; 2023 Feb; 23(3-4):e2100369. PubMed ID: 36094355
[TBL] [Abstract][Full Text] [Related]
18. A combinatorial native MS and LC-MS/MS approach reveals high intrinsic phosphorylation of human Tau but minimal levels of other key modifications.
Drepper F; Biernat J; Kaniyappan S; Meyer HE; Mandelkow EM; Warscheid B; Mandelkow E
J Biol Chem; 2020 Dec; 295(52):18213-18225. PubMed ID: 33106314
[TBL] [Abstract][Full Text] [Related]
19. FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease.
Mair W; Muntel J; Tepper K; Tang S; Biernat J; Seeley WW; Kosik KS; Mandelkow E; Steen H; Steen JA
Anal Chem; 2016 Apr; 88(7):3704-14. PubMed ID: 26877193
[TBL] [Abstract][Full Text] [Related]
20. Mass spectrometry-based detection and assignment of protein posttranslational modifications.
Doll S; Burlingame AL
ACS Chem Biol; 2015 Jan; 10(1):63-71. PubMed ID: 25541750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
